Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells

被引:0
|
作者
Münzel, PA [1 ]
Schmohl, S [1 ]
Heel, H [1 ]
Kälberer, K [1 ]
Bock-Hennig, BS [1 ]
Bock, KW [1 ]
机构
[1] Univ Tubingen, Inst Toxicol, D-72074 Tubingen, Germany
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human colon carcinoma Caco-2 cells were used to study the induction of UDP glucuronosyltransferase (UGT) isoforms UGT1A6, UGT1A9, and UGT2B7 by aryl hydrocarbon receptor agonists and by antioxidant-type inducers with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and t-butylhydroquinone (TBHQ), respectively. Early(PF11) and late-passage clones (TC7) of Caco-2 cells, which show low and high constitutive UGT1A6 expression, respectively, were selected. The following results were obtained: 1) In Caco-2 cells UGT activity (4-methylumbelliferone as substrate) was significantly enhanced by 10 nM TCDD or 40 to 80 mu M TBHQ and 2) duplex reverse-transcription-polymerase chain reaction analysis showed for the first time that the expression of human UGT1A6, UGT1A6, and UGT2B7 was enhanced by 40 to 80 mu M TBHQ; both UGT1A6 and UGT1A9 were induced by 10 nM TCDD, whereas UGT2B7 was not induced by TCDD. The results suggest that at least two human UGTs (UGT1A6 and UGT1A9) are inducible by aryl hydrocarbon receptor agonists and even more isoforms (UGT1A6, UGT1A9, and UGT2B7) are inducible by antioxidant-type inducers in Caco-2 cells.
引用
收藏
页码:569 / 573
页数:5
相关论文
共 50 条
  • [21] Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol
    Ohno, A
    Saito, Y
    Hanioka, N
    Jinno, H
    Saeki, M
    Ando, M
    Ozawa, S
    Sawada, J
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (02) : 235 - 239
  • [22] Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver.
    Mirkov, S.
    Ramirez, J.
    Zhang, W.
    Chen, P.
    Das, S.
    Liu, W.
    Ratain, M. J.
    Innocenti, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S61 - S61
  • [23] Evaluation of UGT protein interactions in human hepatocytes: Effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes
    Konopnicki, Camille M.
    Dickmann, Leslie J.
    Tracy, Jeffrey M.
    Tukey, Robert H.
    Wienkers, Larry C.
    Foti, Robert S.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2013, 535 (02) : 143 - 149
  • [24] EFFECTS OF HISTONE DEACETYLASE INHIBITOR ON UGT1A1 AND UGT1A6 EXPRESSION IN CACO-2 CELLS
    Katoh, Miki
    Asai, Yuki
    Goto, Shoko
    Nadai, Masayuki
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S25 - S25
  • [25] CLONING AND CHARACTERIZATION OF CDNAS ENCODING MOUSE UGT1.6 AND RABBIT UGT1.6 - DIFFERENTIAL INDUCTION BY 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN
    LAMB, JG
    STRAUB, P
    TUKEY, RH
    BIOCHEMISTRY, 1994, 33 (34) : 10513 - 10520
  • [26] Effects of UGT1A3, UGT1A6, and UGT2B7 genetic polymorphisms on plasma concentration of valproic acid in south Chinese epilepsy patients
    Shen, Xiongrong
    Bi, Jingbo
    Liu, Quankun
    Ma, Zhihong
    Min, Lishan
    Xu, Limin
    Yang, Shuixin
    Chen, Yingrong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (04): : 4513 - 4522
  • [27] Differences in the regulation of the UGT1A1, UGT1A6, UGT2B4 and UGT2B7 genes in human liver and small intestine define tissue specific and interindividual glucuronidation activities.
    Strassburg, CP
    Kneip, S
    Topp, J
    Obermayer-Straub, P
    Turkey, RH
    Manns, MP
    HEPATOLOGY, 2000, 32 (04) : 330A - 330A
  • [28] Influence of UGT1A9*3 and UGT2B7 (G-840A) polymorphisms on MPA metabolism in renal transplant recipients
    Djebli, N
    Picard, N
    Le Meur, Y
    Szelag, JC
    Rousseau, A
    Marquet, P
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 246 - 246
  • [29] Kinetic characterisation of S-naproxen glucuronidation by human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7
    Knights, KM
    Tsoutsikos, P
    Bowalgaha, K
    Elliot, DJ
    Miners, JO
    DRUG METABOLISM REVIEWS, 2004, 36 : 135 - 135
  • [30] Two UGT enzymes, UGT1A3 and UGT2B7, are involved in the metabolism of tesaglitazar (GALIDA™)
    Andersson, TB
    Åhlgren, A
    Masimirembwa, CM
    DRUG METABOLISM REVIEWS, 2004, 36 : 131 - 131